sermorelin dosage for: Frequently asked questions

These are common transient effects in the first 2–4 weeks, occurring in 15–20% of users at doses above 250 mcg. The mechanism is vasodilation mediated by GH-induced nitric oxide release. Reducing the dose to 150–200 mcg for one week, then titrating upward by 50 mcg every 5–7 days, allows vascular adaptation without discontinuing the protocol. Persistent symptoms beyond 4 weeks or syncope (fainting) warrants stopping and consulting a prescribing physician. These are rare but indicate possible cardiovascular sensitivity.

Transient facial flushing and mild tachycardia occur in 10–15% of users during the first 10–20 minutes post-injection as Sermorelin triggers acute GH release. This response is benign and typically resolves within 30 minutes. If symptoms persist beyond 45 minutes or worsen over successive doses, reduce the dose to 150 mcg and titrate upward more gradually. Persistent cardiovascular symptoms warrant discontinuation and prescriber consultation.

Increase the dose to 400 mcg nightly and retest IGF-1 at week 12. Non-response at standard doses suggests either impaired pituitary reserve (common in adults over 60) or hepatic IGF-1 synthesis deficiency, which can result from chronic inflammation, malnutrition, or liver dysfunction. If IGF-1 remains unchanged at 400 mcg, switching to a GH secretagogue with a different mechanism. Such as MK 677, a ghrelin receptor agonist that bypasses GHRH pathways. May produce better results.

Increase the dose to 250–300 mcg before concluding non-response. Individual GHRH receptor density varies, and some adults require the upper end of the therapeutic range to saturate receptors fully. Verify injection timing. Administering Sermorelin more than 90 minutes before sleep or during the day eliminates synchronisation with the nocturnal GH pulse, blunting response regardless of dose. If no subjective improvement or IGF-1 elevation occurs after four weeks at 300 mcg, reassess storage conditions and peptide source integrity.

If ambient temperature was below 25°C for fewer than 12 hours, potency loss is likely 10–20%. Still usable but reduced effectiveness. Above 25°C or longer than 12 hours, degradation accelerates to 40–60%. There's no visual indicator of potency loss; the solution remains clear. The practical approach: discard the vial and reconstitute a fresh one. Degraded sermorelin doesn't cause harm, but it wastes the financial investment and delays protocol results by weeks.

Discard it. Reconstituted Sermorelin stored above 8°C for more than four hours loses structural integrity. The peptide denatures irreversibly, and potency cannot be restored by refrigeration. Visual clarity is not a reliable indicator. Denatured peptides remain clear and colourless. Temperature excursions are the most common cause of protocol failure that patients attribute to 'non-response' when the actual issue is degraded product.

The GH response will be significantly blunted. Daytime GHRH secretion is suppressed by somatostatin tone, which blocks Sermorelin's ability to trigger pituitary GH release effectively. Do not double-dose that evening to compensate; simply resume the standard bedtime injection the following night. A single mistimed dose does not derail long-term IGF-1 trends.

Verify injection timing and reconstitution freshness first. Sermorelin administered more than 2 hours before sleep or reconstituted more than 30 days prior loses significant efficacy. If timing and storage are correct, the issue is likely caloric intake: sermorelin preserves lean mass during energy deficit but doesn't build muscle in a surplus. A 2025 metabolic ward study at Yale demonstrated that sermorelin's body composition effects require at least a 300–500 calorie daily deficit to manifest as visible fat loss. Subjects eating at maintenance saw elevated GH and IGF-1 but minimal changes in body composition over 12 weeks.